Menu
Oncology Evolved
Engineering the Next Generation of Off-the-Shelf Cell Therapies
PIPELINE
PRE-CLINICAL
CLINICAL
CAR-T (Allogeneic)
T-ALL/LBL
WU-CART-007
Memory NK (Allogeneic)
AML
WU-NK-101
Solid Tumors
WU-NK-101 + mAb
Solid Tumors
WU-NK-201 Engineered
LATEST NEWS
Wugen to Present New Clinical Data for WU-CART-007 and Preclinical Data for WU-NK-101, Two Investigational Allogeneic Cell Therapies for Challenging Hematologic Cancers, at American Society of Hematology Annual Meeting & Exposition
-- Oral Presentation Highlights Latest Clinical Findings from First Global, In-Human Phase 1/2 Dose-Escalation Study of Anti-CD7 Off-the-Shelf Allogeneic CAR-T…
Wugen Begins First-in-Human Phase 1 Clinical Trial of WU-NK-101, its Lead Allogeneic Memory Natural Killer (NK) Cell Therapy for Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML)
— First Patient Dosed in this Global, Open-Label Study to Assess the Safety and Tolerability of WU-NK-101 in AML —…
Wugen Presents Initial Data from First-in-Human Phase 1/2 Trial of WU-CART-007 at the European Hematology Association (EHA) 2023 Congress
-- WU-CART-007 was well-tolerated in patients with R/R T-ALL/LBL, with low incidence of high-grade CRS and immune-related adverse events -- …
Copyright © 2023 Wugen. All Rights Reserved.
a COGNEO design